Enliven Therapeutics, Inc.

Item 5. Other Information.

During our last fiscal quarter, the following director(s) and officer(s), as defined in Rule 16a-1(f), adopted and/or terminated a “Rule 10b5-1 trading arrangement” as defined in Regulation S-K Item 408:

On January 3, 2026, Anish Patel, Pharm.D., our Chief Operating Officer and, until February 12, 2026, an officer as defined in Rule 16a-1(f), as trustee for The Patel/Dong Family Trust, dated August 24, 2017, terminated the “Rule 10b5-1 trading arrangement” as defined in Regulation S-K Item 408 that had previously been adopted on October 10, 2025. The trading arrangement provided for the sale from time to time of an aggregate of up to 230,000 shares of our common stock and was intended to satisfy the affirmative defense in Rule 10b5-1(c).

On March 6, 2026, Lori Kunkel, M.D., adirector, adopted a “Rule 10b5-1 trading arrangement” as defined in Regulation S-K Item 408 providing for the sale from time to time of an aggregate of up to 20,000 shares of our common stock. The trading arrangement is intended to satisfy the affirmative defense in Rule 10b5-1(c). The duration of the trading arrangement is until July 9, 2027, or earlier if all transactions under the trading arrangement are completed.

On March 18, 2026, Benjamin Hohl, our Chief Financial Officer and an officer as defined in Rule 16a-1(f), adopted a “Rule 10b5-1 trading arrangement” as defined in Regulation S-K Item 408 providing for the sale from time to time of an aggregate of up to 43,090 shares of our common stock. The trading arrangement is intended to satisfy the affirmative defense in Rule 10b5-1(c). The duration of the trading arrangement is until July 1, 2027, or earlier if all transactions under the trading arrangement are completed.

No other officers or directors, as defined in Rule 16a-1(f), adopted and/orterminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement,” as defined in Regulation S-K Item 408, during the last fiscal quarter.